Skip to main content
Vivesto logo

Vivesto — Investor Relations & Filings

Ticker · VIVE ISIN · SE0000722365 LEI · 5493003TZPR4B7QO9L49 ST Manufacturing
Open in API
Filings indexed 1,069 across all filing types
Latest filing 2019-07-05 Share Issue/Capital Cha…
Country SE Sweden
Listing ST VIVE

About Vivesto

https://www.vivesto.com/en/

Vivesto is a specialty pharmaceutical company focused on drug development in oncology. The company aims to provide new therapeutic options for patients suffering from hard-to-treat cancers where significant medical needs exist. Its research and development efforts are centered on creating innovative treatments and enhancing the intravenous delivery of established and novel drugs. The company's lead product is Apealea, a formulation of the cancer drug paclitaxel.

Recent filings

Filing Released Lang Actions
Oasmia and Arwidsro have solved outstanding balances and Arwidsro increases its investment in Oasmia
Share Issue/Capital Change Classification · 99% confidence The document details a specific agreement between Oasmia and its largest shareholder, Arwidsro, concerning the early fulfillment of a financing obligation, warrant utilization, and debt settlement. This transaction results in a significant change to the company's capital structure (liabilities decreasing, equity increasing, share count increasing). This type of corporate action, involving financing, capital structure changes, and debt resolution, aligns best with the 'Capital/Financing Update' category. Although it mentions the 'year-end report' as a source for more facts, the core content is the announcement of the financing agreement itself, not the report. It is not a standard regulatory filing like 10-K or ER, but a specific corporate finance event announcement. Therefore, 'CAP' is the most appropriate classification.
2019-07-05 English
Oasmia och Arwidsro har löst utestående mellanhavanden och Arwidsro satsar ytterligare i Oasmia
Capital/Financing Update Classification · 98% confidence The document is a press release dated July 5, 2019, announcing a resolution between Oasmia and its largest shareholder, Arwidsro, regarding outstanding financial obligations and a new capital injection. Key elements include the settlement of financing commitments (75 mkr), the utilization of warrants, a cash acquisition of a claim, and the resulting decrease in debt and increase in equity. This type of announcement, detailing significant financial restructuring, capital changes, and shareholder agreements outside of standard periodic reports (like 10-K or IR), fits best under 'Capital/Financing Update' (CAP). It is not a full Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV). While it involves share counts, the primary focus is the resolution of financial disputes and capital infusion, making CAP the most accurate classification.
2019-07-05 Swedish
Oasmia and Arwidsro have solved outstanding balances and Arwidsro increases its investment in Oasmia
Capital/Financing Update Classification · 98% confidence The document is a press release dated July 5, 2019, announcing a specific financial transaction between Oasmia and its largest shareholder, Arwidsro, involving the settlement of outstanding balances, early fulfillment of a financing obligation (SEK 75 million), utilization of warrants, and the acquisition of claims. This transaction results in a decrease in liabilities, an increase in equity, and an immediate positive liquidity effect. This content directly relates to changes in the company's capital structure, financing arrangements, and debt settlement. This aligns best with the 'Capital/Financing Update' category (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it details a specific, material financing event.
2019-07-05 English
Oasmia appoints Business Advisory Board
Board/Management Information Classification · 95% confidence The document announces the appointment of a new Business Advisory Board for Oasmia Pharmaceutical AB. It provides details on the board members' backgrounds and the strategic purpose of the board. While it mentions an attachment, the core content is a corporate announcement regarding management/board structure. Since it specifically details the formation of a new advisory board, it falls under the 'Board/Management Information' category.
2019-07-04 English
Oasmia appoints Business Advisory Board
Board/Management Information Classification · 95% confidence The document announces the appointment of a new Business Advisory Board for Oasmia Pharmaceutical AB. It provides details on the board members' backgrounds and the strategic purpose of the board. While it mentions an attachment, the core content is a corporate announcement regarding management/board structure. Since it specifically details the formation of a new advisory board, it falls under the 'Board/Management Information' category.
2019-07-04 English
Oasmia appoints Business Advisory Board
Board/Management Information Classification · 98% confidence The document announces the appointment of members to the company's Business Advisory Board and provides biographies for the new members. This directly relates to changes in the company's advisory structure and key personnel involved in strategy and commercialization. This fits the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management, extending logically to key advisory boards that support management functions.
2019-07-04 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.